The Liquid Biopsy Market is expected to reach USD 13.8 billion by 2030 at 12.4% CAGR during the forecast period 2022-2030. A liquid biopsy is a largely non-invasive, sampling and analysis of liquid state biological tissue for diagnostic and monitoring diseases such as cancer. Liquid biopsy is the direct clinical application of two advances in medical science, namely, human genome sequencing and rising sensitivity of detecting techniques and assays.
Liquid biopsy capitalizes on the qualitative and quantitative difference between different biomarkers such as cell-free DNA, circulating tumor cells (CTCs), cell-free RNA (cfRNA) fragments, methylated ctDNA, and miRNA in a patient's blood. Although some of these fragments are released even during other conditions such as trauma, there exists a quantitative difference in the form of their composition and concentration as well as their degree of fragmentation.
Liquid Biopsy Market Dynamics
Liquid biopsies avoid the painful extraction of the tissue sample and thereby eliminate the pain associated with the procedure. For instance, a majority of liquid samples used in the procedure are blood and urine and are easily collected without much pain. A few examples however involve painful procedure such as spinal fluid. Thus, liquid biopsy reduces the apprehension of patients regarding pain. It also provides a safe and effective method for patients for whom a tissue biopsy is not possible due to associated risks, such as lung cancer patients with tumors too dangerously close to the heart.
Liquid Biopsy Market Segmentation
The global liquid biopsy market has been segmented into biomarker types, application, samples, and end user.
Based on biomarker types, the global market is segmented into circulating tumor cells (CTCS), circulating tumor DNA (CTDNA), extracellular vesicles (EVS), and others.
Based on application, the global market has been segmented into cancer, reproductive health, and others.
Based on sample, the global market is segmented into blood sample, urine sample, forensic, and other sample.
Based on end user, the global market is segmented into hospitals and laboratories, academic and research centers, and other end users. Advances in detection technologies such as digital PCR, advanced cell capture technology, and multi-panel detection were the other driving factors for the commercial application of the technology.
Liquid Biopsy Market Key Players
The major players in the global liquid biopsy market are Guardant Health, Inc. (US), Trovagene, Inc. (California), RainDance Technologies, Inc. (US), Agena Bioscience Inc. (California), Admera Health (US), Biocept, Inc. KGaA (US), Circulogene Theranostics (Alabama), Inivata Ltd (UK), SAGA Diagnostics AB (Sweden), and Exosome Diagnostics (Massachusetts).
Some of the key strategies followed by the players operating in the global market are adopting various strategies to expand their global liquid biopsy business and enhance their market share.
Liquid Biopsy Market Regional Analysis
The global liquid biopsy in the healthcare market, on the basis of region, is segmented into North America, Europe, Asia-Pacific, and Middle East & Africa.
North America accounted for the largest market share while Asia-Pacific is the fastest-growing market. The technology of liquid biopsy was developed in the US and several European countries, which is reflected in the dominance of these two regions in their respective market share. The European market is projected to grow at the highest CAGR. The venture capital available to life sciences companies has more than doubled from 2001 to 2010. In Europe, the UK accounts for almost 20% of all investments, and almost 20% of the UK venture capital was invested in the healthcare sector.
Asia-Pacific is the fastest-growing market and is expected to grow at a exponentail CAGR during the forecasted period. The Middle East & Africa is expected to have a limited market but steady growth. In 2012, 14 million new cases and 8.2 million cancer-related deaths were reported worldwide, and this number is projected to reach 22 million within the next two decades. Africa, Asia-Pacific, and Central and South America account for almost 2/3rd of the cases and 3/4th of the deaths.
Liquid Biopsy Market Segmental Overview
Global Market by Test Type
Global Market by Application
Global Market by Sample
Global Market by End Users
Global Market by Region
Available Additional Customizations
|Market Size||USD 13.8 Billion|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Biomarker Types, Application, Sample and End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Guardant Health, Inc. (US), Trovagene, Inc. (California), RainDance Technologies, Inc. (US), Agena Bioscience Inc. (California), Admera Health (US), Biocept, Inc. KGaA (US), Circulogene Theranostics (Alabama), Inivata Ltd (UK), SAGA Diagnostics AB (Sweden), and Exosome Diagnostics (Massachusetts)|
|Key Market Opportunities||
|Key Market Drivers||
The liquid biopsy market is projected to reach a valuation of USD 13.8 Billion by 2030.
The global liquid biopsy market is projected to grow at approximately 12.4% CAGR during forecast period (2022-2030).
Advancements in biopsy procedures.
North America holds the largest share in the global liquid biopsy market followed by Europe and Asia Pacific, respectively.
Trovagene, Inc. (California), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), Admera Health (US), Agena Bioscience Inc. (California), Biocept, Inc. KGaA (US), Inivata Ltd (UK), Circulogene Theranostics (Alabama), Exosome Diagnostics (Massachusetts), and SAGA Diagnostics AB (Sweden), are some of the major players operating in the liquid biopsy market.